First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·First implantable therapy in development · Built on published SGB evidence · No approved implantable competitor ·
Investors

A first-in-class implantable therapy for treatment-resistant PTSD.

24M active PTSD patients in the US and EU, of whom 8.4M are treatment-resistant and hyperarousal-dominant: our target population. No approved implantable competitor. Built on published stellate ganglion block evidence.

Why now

01 · 02
01

The mechanism is validated

Stellate ganglion block reduces PTSD symptoms in a randomized sham-controlled trial (JAMA Psychiatry, 2020), with 70 to 75% response reported in uncontrolled case series (VA Evidence Brief, 2017). Its effect is temporary. TraumaTone is designed to make it durable. Device safety and efficacy in humans remain to be demonstrated: that is what this round funds.

02

No durable solution exists

Stellate ganglion blocks must be repeated every few months, and no implantable, programmable option is approved. No competing percutaneous stellate ganglion implant program has been announced.

03

The regulatory path is open

FDA authorized the first neuromodulation device for PTSD in 2026, and Breakthrough Device and expedited coverage pathways exist for severe unmet needs. Government and military payers are increasingly active in PTSD care.

The opportunity

02 · 02
24M
Active PTSD patients, US + EU
8.4M
Treatment-resistant, hyperarousal-dominant
1
Positive sham-controlled RCT (JAMA Psychiatry, 2020)
0
Approved implantable competitors

“A durable answer to a proven mechanism.”

Request investor materials →

Stimalia

Bioelectronic medicine · Louvain La Neuve · est. 2025